Aktienanalyse zu HCA Healthcare Inc (HCA)HCAHCA Healthcare Inc

HCA Healthcare, Inc. is a health care services company. The Company provides acute care hospitals, ambulatory surgery centers (ASCs), freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, comprehensive rehabilitation and physical therapy centers, hospices, and various other facilities. Its general, acute care hospitals provide a full range of services to accommodate such medical specialties as internal medicine, general surgery, cardiology, oncology, neurosurgery, orthopedics and obstetrics, as well as diagnostic and emergency services. Its behavioral hospitals provide a full range of mental health care services through inpatient, partial hospitalization and outpatient settings. It operates approximately 190 hospitals comprised of 179 general acute care hospitals, seven behavioral hospitals, and four rehabilitation hospitals and its facilities are in 19 states and the United Kingdom. It operates in the Healthcare sector (SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC industry).

HCA Healthcare is currently priced at $417.82, which is below several analyst price targets, including a $425 target from JPMorgan and a $485 target from Goldman Sachs. However, the stock has a relatively low RSI of 48.755, indicating it is not in overbought territory, but the recent insider selling has increased by 1487.91%, which raises concerns about insider confidence. Given these factors, it may be prudent to hold rather than buy at this time, as the stock faces challenges such as declining cash flow and mixed analyst sentiment.

22 analysts cover HCA: 16 rate it Buy, 6 Hold and 0 Sell. The average price target is 491.89.